MarÃ-a G Barderas

List of Publications by Year
in descending order

103 papers	2,108 citations	218381 26 h-index	288905 40 g-index
108 all docs	108 docs citations	108 times ranked	3202 citing authors

#	Article	IF	Citations
1	Identification of a urine metabolomic signature in patients with advanced-stage chronic kidney disease. Kidney International, 2014, 85, 103-111.	2.6	135
2	Differential Role of Human Choline Kinase Î± and Î² Enzymes in Lipid Metabolism: Implications in Cancer Onset and Treatment. PLoS ONE, 2009, 4, e7819.	1.1	88
3	Metabolomic Profiling for Identification of Novel Potential Biomarkers in Cardiovascular Diseases. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-9.	3.0	81
4	Quest for Novel Cardiovascular Biomarkers by Proteomic Analysisâ€. Journal of Proteome Research, 2005, 4, 1181-1191.	1.8	80
5	A Proteomic Focus on the Alterations Occurring at the Human Atherosclerotic Coronary Intima. Molecular and Cellular Proteomics, 2011, 10, M110.003517.	2.5	71
6	Kidney tissue proteomics reveals regucalcin downregulation in response to diabetic nephropathy with reflection in urinary exosomes. Translational Research, 2015, 166, 474-484.e4.	2.2	62
7	Proteomic Profile of Human Aortic Stenosis: Insights into the Degenerative Process. Journal of Proteome Research, 2012, 11, 1537-1550.	1.8	57
8	Secretome analysis of atherosclerotic and non-atherosclerotic arteries reveals dynamic extracellular remodeling during pathogenesis. Journal of Proteomics, 2012, 75, 2960-2971.	1.2	56
9	Circulating Human Monocytes in the Acute Coronary Syndrome Express a Characteristic Proteomic Profile. Journal of Proteome Research, 2007, 6, 876-886.	1.8	52
10	Analysis of the Plasma Proteome Associated with Acute Coronary Syndrome: Does a Permanent Protein Signature Exist in the Plasma of ACS Patients?. Journal of Proteome Research, 2010, 9, 4420-4432.	1.8	52
11	Deregulation of smooth muscle cell cytoskeleton within the human atherosclerotic coronary media layer. Journal of Proteomics, 2013, 82, 155-165.	1.2	49
12	Atorvastatin modulates the profile of proteins released by human atherosclerotic plaques. European Journal of Pharmacology, 2007, 562, 119-129.	1.7	48
13	Role of matrix metalloproteinase-9Âin chronic kidney disease: a new biomarker of resistant albuminuria. Clinical Science, 2016, 130, 525-538.	1.8	48
14	Plasma metabolomics reveals a potential panel of biomarkers for early diagnosis in acute coronary syndrome. Metabolomics, 2014, 10, 414-424.	1.4	45
15	Depletion of High-Abundance Proteins in Plasma by Immunoaffinity Subtraction for Two-Dimensional Difference Gel Electrophoresis Analysis. , 2007, 357, 351-364.		44
16	Identification of a circulating microvesicle protein network involved in ST-elevation myocardial infarction. Thrombosis and Haemostasis, 2014, 112, 716-726.	1.8	39
17	MALDI-Imaging Mass Spectrometry: a step forward in the anatomopathological characterization of stenotic aortic valve tissue. Scientific Reports, 2016, 6, 27106.	1.6	39
18	iTRAQ proteomic analysis of extracellular matrix remodeling in aortic valve disease. Scientific Reports, 2015, 5, 17290.	1.6	36

#	Article	IF	Citations
19	Citric Acid Metabolism in Resistant Hypertension. Hypertension, 2017, 70, 1049-1056.	1.3	36
20	KLK1 and ZG16B proteins and arginineâ€“proline metabolism identified as novel targets to monitor atherosclerosis, acute coronary syndrome and recovery. Metabolomics, 2015, 11, 1056-1067.	1.4	35
21	Cytoskeleton deregulation and impairment in amino acids and energy metabolism in early atherosclerosis at aortic tissue with reflection in plasma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 725-732.	1.8	35
22	Patients with calcific aortic stenosis exhibit systemic molecular evidence of ischemia, enhanced coagulation, oxidative stress and impaired cholesterol transport. International Journal of Cardiology, 2016, 225, 99-106.	0.8	34
23	Proteomic characterization of human coronary thrombus in patients with ST-segment elevation acute myocardial infarction. Journal of Proteomics, 2014, 109, 368-381.	1.2	33
24	Urinary exosomes reveal protein signatures in hypertensive patients with albuminuria. Oncotarget, 2017, 8, 44217-44231.	0.8	33
25	Inside human aortic stenosis: A proteomic analysis of plasma. Journal of Proteomics, 2012, 75, 1639-1653.	1.2	31
26	Comparison of the Protein Profile of Established and Regressed Hypertension-Induced Left Ventricular Hypertrophy. Journal of Proteome Research, 2006, 5, 404-413.	1.8	29
27	Potential blood biomarkers for stroke. Expert Review of Proteomics, 2012, 9, 437-449.	1.3	28
28	Hypertensive patients exhibit an altered metabolism. A specific metabolite signature in urine is able to predict albuminuria progression. Translational Research, 2016, 178, 25-37.e7.	2.2	28
29	Molecular anatomy of ascending aorta in atherosclerosis by MS Imaging: Specific lipid and protein patterns reflect pathology. Journal of Proteomics, 2015, 126, 245-251.	1.2	27
30	Proteomic Analysis of Early Left Ventricular Hypertrophy Secondary to Hypertension: Modulation by Antihypertensive Therapies. Journal of the American Society of Nephrology: JASN, 2006, 17, S159-S164.	3.0	24
31	Tissue proteomics in atherosclerosis: elucidating the molecular mechanisms of cardiovascular diseases. Expert Review of Proteomics, 2009, 6, 395-409.	1.3	24
32	Urinary alpha-1 antitrypsin and CD59 glycoprotein predict albuminuria development in hypertensive patients under chronic renin-angiotensin system suppression. Cardiovascular Diabetology, 2016, 15, 8.	2.7	24
33	Atorvastatin modifies the protein profile of circulating human monocytes after an acute coronary syndrome. Proteomics, 2009, 9, 1982-1993.	1.3	23
34	Modification of the Secretion Pattern of Proteases, Inflammatory Mediators, and Extracellular Matrix Proteins by Human Aortic Valve is Key in Severe Aortic Stenosis. Molecular and Cellular Proteomics, 2013, 12, 2426-2439.	2.5	23
35	Valvular Aortic Stenosis: A Proteomic Insight. Clinical Medicine Insights: Cardiology, 2010, 4, CMC.S3884.	0.6	22
36	Characterization of the Human Atheroma Plaque Secretome by Proteomic Analysis. , 2007, 357, 141-150.		21

#	Article	IF	Citations
37	Kalirin and CHD7: novel endothelial dysfunction indicators in circulating extracellular vesicles from hypertensive patients with albuminuria. Oncotarget, 2017, 8, 15553-15562.	0.8	20
38	A novel methodology for the analysis of membrane and cytosolic subâ€proteomes of erythrocytes by 2â€DE. Electrophoresis, 2009, 30, 4095-4108.	1.3	18
39	Targeting antigens to an invariant epitope of the MHC Class II DR molecule potentiates the immune response to subunit vaccines. Virus Research, 2011, 155, 55-60.	1.1	18
40	Prediction of development and maintenance of high albuminuria during chronic reninâ€“angiotensin suppression by plasma proteomics. International Journal of Cardiology, 2015, 196, 170-177.	0.8	18
41	Plasma Molecular Signatures in Hypertensive Patients With Reninâ€“Angiotensin System Suppression. Hypertension, 2016, 68, 157-166.	1.3	18
42	A role for the membrane proteome in human chronic kidney disease erythrocytes. Translational Research, 2012, 160, 374-383.	2.2	17
43	Aortic stenosis: a general overview of clinical, pathophysiological and therapeutic aspects. Expert Review of Cardiovascular Therapy, 2013, 11, 239-250.	0.6	17
44	Proteomic approach in the search of new cardiovascular biomarkers. Kidney International, 2005, 68, S103-S107.	2.6	16
45	Heart Mitochondrial Proteome Study Elucidates Changes in Cardiac Energy Metabolism and Antioxidant PRDX3 in Human Dilated Cardiomyopathy. PLoS ONE, 2014, 9, e112971.	1.1	16
46	ATP synthase subunit alpha and LV mass in ischaemic human hearts. Journal of Cellular and Molecular Medicine, 2015, 19, 442-451.	1.6	15
47	Vascular proteomics. Proteomics - Clinical Applications, 2007, 1, 1102-1122.	0.8	14
48	An optimum method designed for 2â€Ð DIGE analysis of human arterial intima and media layers isolated by laser microdissection. Proteomics - Clinical Applications, 2009, 3, 1174-1184.	0.8	14
49	A clinical perspective on the utility of alpha 1 antichymotrypsin for the early diagnosis of calcific aortic stenosis. Clinical Proteomics, 2017, 14, 12.	1.1	14
50	Rapid, Automated, and Specific Immunoassay to Directly Measure Matrix Metalloproteinase-9â€“Tissue Inhibitor of Metalloproteinase-1 Interactions in Human Plasma Using AlphaLISA Technology: A New Alternative to Classical ELISA. Frontiers in Immunology, 2017, 8, 853.	2.2	14
51	Identification of six cardiovascular risk biomarkers in the young population: A promising tool for early prevention. Atherosclerosis, 2019, 282, 67-74.	0.4	14
52	Lipid and protein maps defining arterial layers in atherosclerotic aorta. Data in Brief, 2015, 4, 328-331.	0.5	13
53	Immune system deregulation in hypertensive patients chronically RAS suppressed developing albuminuria. Scientific Reports, 2017, 7, 8894.	1.6	13
54	Plasma CD5L and non-invasive diagnosis of acute heart rejection. Journal of Heart and Lung Transplantation, 2020, 39, 257-266.	0.3	13

#	Article	IF	Citations
55	Frequency and Prognosis of Treated Hypertensive Patients According to Prior and New Blood Pressure Goals. Hypertension, 2019, 74, 130-136.	1.3	12
56	Vascular Proteomics. Methods in Molecular Biology, 2013, 1000, 1-20.	0.4	11
57	Urinary metabolic signatures reflect cardiovascular risk in the young, middle-aged, and elderly populations. Journal of Molecular Medicine, 2020, 98, 1603-1613.	1.7	10
58	ObtenciÃ³n de un protocolo Ã³ptimo para el anÃ¡lisis proteÃ³mico de vÃ¡lvulas aÃ³rticas humanas sanas y estenÃ³ticas. Revista Espanola De Cardiologia, 2010, 63, 46-53.	0.6	9
59	A multicentric study to evaluate the use of relative retention times in targeted proteomics. Journal of Proteomics, 2017, 152, 138-149.	1.2	9
60	Cardiovascular Risk Stratification Based on Oxidative Stress for Early Detection of Pathology. Antioxidants and Redox Signaling, 2021, 35, 602-617.	2.5	9
61	Underperformance of clinical risk scores in identifying imaging-based high cardiovascular risk in psoriasis: results from two observational cohorts. European Journal of Preventive Cardiology, 2022, 29, 591-598.	0.8	9
62	Characterization of Circulating Human Monocytes by Proteomic Analysis. , 2007, 357, 319-328.		8
63	Potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals. Scientific Reports, 2018, 8, 4802.	1.6	8
64	Lifetime cardiovascular risk is associated with a multimarker score of systemic oxidative status in young adults independently of traditional risk factors. Translational Research, 2019, 212, 54-66.	2.2	8
65	AsociaciÃ³n entre disminuciÃ³n de la funciÃ³n renal y actividad metaloproteinasa-9 en el paciente hipertenso. Nefrologia, 2019, 39, 184-191.	0.2	8
66	Oxidized Low-Density Lipoprotein Associates with Ventricular Stress in Young Adults and Triggers Intracellular Ca2+ Alterations in Adult Ventricular Cardiomyocytes. Antioxidants, 2020, 9, 1213.	2.2	7
67	Diabetes Mellitus and Its Implications in Aortic Stenosis Patients. International Journal of Molecular Sciences, 2021, 22, 6212.	1.8	7
68	Early renal and vascular damage within the normoalbuminuria condition. Journal of Hypertension, 2021, 39, 2220-2231.	0.3	7
69	Multiple Reaction Monitoring (MRM) of Plasma Proteins in Cardiovascular Proteomics. Methods in Molecular Biology, 2013, 1000, 191-199.	0.4	6
70	Recent advances and clinical insights into the use of proteomics in the study of atherosclerosis. Expert Review of Proteomics, 2017, 14, 701-713.	1.3	6
71	A comprehensive study of calcific aortic stenosis: from rabbit to human samples. DMM Disease Models and Mechanisms, 2018, 11, .	1.2	6
72	Association between renal dysfunction and metalloproteinase (MMP)-9 activity in hypertensive patients. Nefrologia, 2019, 39, 184-191.	0.2	6

#	Article	IF	Citations
73	TCA Cycle and Fatty Acids Oxidation Reflect Early Cardiorenal Damage in Normoalbuminuric Subjects with Controlled Hypertension. Antioxidants, 2021, 10, 1100.	2.2	6
74	Urine Haptoglobin and Haptoglobin-Related Protein Predict Response to Spironolactone in Patients With Resistant Hypertension. Hypertension, 2019, 73, 794-802.	1.3	6
75	The Influence of Coronary Artery Disease in the Development of Aortic Stenosis and the Importance of the Albumin Redox State. Antioxidants, 2022, 11, 317.	2.2	6
76	Development of an Optimal Protocol for the Proteomic Analysis of Stenotic and Healthy Aortic Valves. Revista Espanola De Cardiologia (English Ed), 2010, 63, 46-53.	0.4	5
77	The plasma proteomic signature as a strategic tool for early diagnosis of acute coronary syndrome. Proteome Science, 2014, 12, 43.	0.7	5
78	Comprehensive Proteomic Profiling of Pressure Ulcers in Patients with Spinal Cord Injury Identifies a Specific Protein Pattern of Pathology. Advances in Wound Care, 2020, 9, 277-294.	2.6	5
79	Why Does COVID-19 Affect Patients with Spinal Cord Injury Milder? A Case-Control Study: Results from Two Observational Cohorts. Journal of Personalized Medicine, 2020, 10, 182.	1.1	5
80	Novel molecular plasma signatures on cardiovascular disease can stratify patients throughout life. Journal of Proteomics, 2020, 222, 103816.	1.2	5
81	Subclinical Liver Disease Is Associated with Subclinical Atherosclerosis in Psoriasis: Results from Two Observational Studies. Journal of Investigative Dermatology, 2022, 142, 88-96.	0.3	5
82	Secretome of Human Aortic Valves. Methods in Molecular Biology, 2013, 1005, 237-243.	0.4	4
83	Characterization of Membrane and Cytosolic Proteins of Erythrocytes. Methods in Molecular Biology, 2013, 1000, 71-80.	0.4	4
84	Translational science in albuminuria: a new view of de novo albuminuria under chronic RAS suppression. Clinical Science, 2018, 132, 739-758.	1.8	4
85	Analysis of Global Oxidative Status Using Multimarker Scores Reveals a Specific Association Between Renal Dysfunction and Diuretic Therapy in Older Adults. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 1198-1205.	1.7	4
86	Contribution of proteomics to the management of vascular disorders. Translational Proteomics, 2015, 7, 3-14.	1.2	3
87	Proteomic investigations into hypertension: whatâ€™s new and how might it affect clinical practice?. Expert Review of Proteomics, 2019, 16, 583-591.	1.3	3
88	Differential metabolic profile associated with the condition of normoalbuminuria in the hypertensive population. Nefrologia, 2020, 40, 439-445.	0.2	3
89	Effects of Growth Hormone Treatment and Rehabilitation in Incomplete Chronic Traumatic Spinal Cord Injury: Insight from Proteome Analysis. Journal of Personalized Medicine, 2020, 10, 183.	1.1	3
90	Differential Protein Expression Analysis of Degenerative Aortic Stenosis by iTRAQ Labeling. Methods in Molecular Biology, 2013, 1005, 109-117.	0.4	2

#	Article	IF	Citations
91	Laser Microdissection and Saturation Labeling DIGE Method for the Analysis of Human Arteries. Methods in Molecular Biology, 2013, 1000, 21-32.	0.4	2
92	Patient Management in Aortic Stenosis: Towards Precision Medicine through Protein Analysis, Imaging and Diagnostic Tests. Journal of Clinical Medicine, 2020, 9, 2421.	1.0	2
93	Perfil metabolÃ³mico diferenciador asociado a la condiciÃ³n de normoalbuminuria en la poblaciÃ³n hipertensa. Nefrologia, 2020, 40, 440-445.	0.2	2
94	A Comparative Study of Immunodepletion and Equalization Methods for Aortic Stenosis Human Plasma. Methods in Molecular Biology, 2013, 1005, 245-256.	0.4	1
95	Two-Dimensional Electrophoresis and Identification by Mass Spectrometry. Methods in Molecular Biology, 2017, 1592, 71-78.	0.4	1
96	Proteomic Analysis of Blood Extracellular Vesicles in Cardiovascular Disease by LC-MS/MS Analysis. Methods in Molecular Biology, 2017, 1619, 141-149.	0.4	1
97	Progression of Renal Insufficiency in Patients with Essential Hypertension Treated with Renin Angiotensin Aldosterone System Blockers: An Electrocardiographic Correlation. Diseases (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlock	1.4	1
98	Aportaciones de la proteÃ³mica al laboratorio clÃnico. Revista Del Laboratorio ClÃnico, 2011, 4, 214-224.	0.1	0
99	Characterization and Analysis of Human Arterial Tissue Secretome by 2-DE and nLC-MS/MS. Methods in Molecular Biology, 2013, 1000, 81-90.	0.4	0
100	Application of Metabolomics to Cardiovascular and Renal Disease Biomarker Discovery. Comprehensive Analytical Chemistry, 2014, , 279-308.	0.7	0
101	Prediction of the early response to spironolactone in resistant hypertension by the combination of matrix metalloproteinase-9 activity and arterial stiffness parameters. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, , .	1.4	0
102	Proteomics Toward Biomarkers Discovery and Risk Assessment. , 2013, , 115-130.		0
103	Prioritization of Candidate Biomarkers for Degenerative Aortic Stenosis through a Systems Biology-Based In-Silico Approach. Journal of Personalized Medicine, 2022, 12, 642.	1.1	0